Background Conventional balloon angioplasty of intracoronary thrombus is associated with a high incidence of abrupt closure, distal embolization, and no-reflow phenomenon. The purpose of this study was to assess a new technique for treating intracoronary thrombus consisting of the local delivery of urokinase directly to the angioplasty site with urokinasecoated hydrogel balloons.
Inhibition of Platelet Deposition
T he optimal method for treating intracoronary thrombus during coronary angioplasty is currently unknown. Conventional angioplasty of thrombus and thrombus-containing stenoses is associated with an increased incidence of abrupt thrombotic closure, distal embolization, and no-reflow phenomenon. [1] [2] [3] [4] [5] Compared with angioplasty of nonthrombotic lesions, percutaneous transluminal coronary angioplasty in this circumstance leads to a higher rate of myocardial infarction, emergency coronary artery by-We hypothesized that use of a urokinase-coated hydrogel balloon in an artery with intracoronary thrombus would create a local environment of relatively high urokinase concentration during balloon inflation, resulting in enhanced thrombolysis. Moreover, intramural deposition of the urokinase with the hydrogel system could theoretically produce a localized reservoir of drug at the angioplasty site that could inhibit ongoing platelet deposition and thrombus formation. To test these hypotheses, we designed this study with four specific goals: first, to test in vitro the ability of hydrogel balloons to absorb urokinase, retain surface-bound drug during blood exposure, and transfer drug to the arterial wall during balloon inflation; second, to measure in vivo urokinase washoff from the hydrogel balloon surface in the intact circulation and intramural drug deposition during balloon angioplasty; third, to assess in vivo the effect of local urokinase delivery on platelet deposition after conventional balloon angioplasty; and fourth, to test in patients the ability of urokinase-coated balloons to treat intracoronary thrombus and abrupt thrombotic closure after conventional angioplasty of thrombuscontaining coronary stenoses.
Methods

Equipment
The local drug-delivery system used in this study consists of a standard angioplasty catheter with a hydrogel compound (Hydro Plus, Mansfield/Boston Scientific Corp) coating a 2-to 4-cm polyethylene balloon. The hydrogel coating consists of a latticework of polyacrylic acid chains that are adhered to the balloon surface. At intervals along their length, the polymers are covalently linked to one another. When the hydrogel contacts an aqueous environment, it absorbs water, and the lattice begins to swell and form a stable matrix of polymer and water. Any agents dissolved in the water will also be incorporated into this matrix. The thickness of the coating ranges from 5 gtm when dry to 25 ,um when fully saturated with water.
Loading of Urokinase Onto Hydrogel Balloons
All balloons used in this study were loaded with urokinase by immersing the inflated balloon at 2 atm pressure into a concentrated urokinase solution (50 000 U/mL), deflating the balloon while still in solution, and allowing the balloon to dry under ambient conditions. For in vitro and in vivo pharmacokinetic studies, '251-labeled urokinase (New England Nuclear) was used to measure the amount of drug. Urokinase was radiolabeled with 125J by the Bolton Hunter method and suspended in Abbokinase (50 000 U/mL) (Abbott Laboratories) with a final specific activity of 1 mCi/50 000 U. A known quantity of the radiolabeled urokinase solution was counted in a gamma counter for determination of the relation between 1251 counts per minute and urokinase concentration. Counts per minute measured from balloon surfaces and arterial segments were subsequently converted to microliters of absorbed fluid and units of urokinase after subtraction of background counts.
In Vitro Pharmacokinetic Studies
We performed four in vitro pharmacokinetic protocols to determine the ability of hydrogel balloons to absorb urokinase, retain surface-bound drug during blood exposure, and transfer drug to the arterial wall during balloon dilatation. A total of 86 hydrogel and 12 nonhydrogel balloons were used in this part of the study.
Protocol 1
To determine the optimal loading method for maximizing the amount of urokinase absorbed by the balloon surface, we immersed twenty-four 3.5-mm hydrogel balloons into the radiolabeled urokinase solution using the following four techniques: immersion for 30 seconds (n=6), immersion twice for 30 seconds (n=6), immersion for 60 seconds (n=6), and immersion for 5 minutes (n=6). After urokinase loading, all balloons were excised from their balloon shafts and counted in a gamma counter for measurement of drug absorption.
Protocol 2
To determine the absolute amount of urokinase absorbed by hydrogel balloons of various sizes, we immersed 36 hydrogel balloons ranging in size from 2 to 8 mm into the radiolabeled urokinase solution for 60 seconds and then counted them in a gamma counter. Drug absorption on the following balloon sizes was assessed: 2 mm (n=6), 2.5 mm (n=6), 3 .0 mm (n=6), 3 .5 mm (n=6), 7 mm (n=6), and 8 mm (n=6).
Protocol 3
To determine the effect of blood exposure on urokinase retention by the hydrogel balloon surface, we initially loaded twelve 3.5-mm hydrogel balloons with urokinase by immersion into the radiolabeled urokinase solution for 60 seconds and then agitated them in test tubes containing 10 mL anticoagulated porcine blood for either 60 (n=6) or 120 (n=6) seconds. All 12 balloons were counted in a gamma counter after initial drug loading and then after blood exposure.
Drug retention by the hydrogel balloons was compared with twelve 3.5-mm nonhydrogel balloons (Mansfield/Boston Scientific) that were also immersed into the radiolabeled urokinase solution for 60 seconds and then agitated in blood for either 60 (n=6) or 120 (n=6) seconds exactly as described above for hydrogel balloons.
Protocol 4
To document urokinase transfer from the hydrogel surface to the arterial wall, we dilated 14 freshly harvested porcine peripheral or coronary arteries (4 carotid, 4 iliac, 6 coronary) in vitro with fourteen 3-mm (n=6) or 8-mm (n=8) hydrogel balloons that had been loaded with radiolabeled urokinase by immersion for 60 seconds. Before in vitro angioplasty, 7 of the 14 balloons were agitated in blood for 60 seconds. All balloon dilations were performed for 60 seconds with an inflation pressure of 6 atm and with a balloon-to-artery ratio of approximately 1.3:1. After in vitro angioplasty, the lumen of all dilated vessels was flushed with saline, and then the arterial segment was counted in a gamma counter. The number of urokinase counts in the arteries was compared with the number of counts on 12 equal-sized control balloons that were similarly loaded with urokinase and then counted in a gamma counter.
In Vivo Pharmacokinetic Studies
We performed two in vivo pharmacokinetic protocols to assess urokinase washoff from the hydrogel balloon surface in the intact circulation and the quantity of urokinase intramurally deposited during balloon angioplasty. Ten New Zealand rabbits (3 to 5 kg) were used in this study. Each animal was anesthetized with ketamine (50 mg/kg IM) and xylazine (5 mg/kg IM), and a SF introducer was placed in the right carotid artery using standard surgical techniques. A total of 32 hydrogel balloons and 24 nonhydrogel balloons were used.
Protocol 1
To measure in vivo drug washoff in the intact circulation, we counted 24`251-labeled, urokinase-loaded 3-mm hydrogel balloons in a gamma counter after initial drug loading (n=6) or after introduction into the rabbit circulation through the carotid sheath for 30 (n=6), 60 (n=6), or 120 (n=6) seconds. Balloon counts were compared with twenty-four 3-mm nonhydrogel balloons measured similarly after drug loading (n=6) or in vivo exposure for 30 (n=6), 60 (n=6), or 120 (n=6) seconds. A total of six rabbits were studied with six balloons used in each rabbit. After removal of each balloon, the arterial sheath was flushed with saline.
Protocol 2
For measurement of intramural drug deposition during in vivo balloon angioplasty, four rabbits underwent balloon dilatation of both iliac arteries with radiolabeled urokinase-coated 3-mm hydrogel balloons. For each dilation, a 0.014-inch angioplasty guidewire was introduced through the carotid sheath and advanced to the femoral artery under fluoroscopic guidance. After guidewire placement, each balloon was advanced through the carotid sheath over the guidewire to the level of the iliac artery. Balloon position was chosen to achieve a balloon-to-artery ratio of 1:1. All inflations were performed for 90 seconds at 6 atm. After dilatation of both iliac vessels, the dilated vessels were surgically removed, gently flushed with saline, and counted in a gamma counter for measurement of intramural`2I-urokinase. Arterial counts were compared with six 3-mm hydrogel balloons that were counted immediately after drug loading.
In Vivo Platelet Deposition Studies
Seven 3-to 4-month-old (20 to 30 kg) male Yorkshire swine were used for determination of the effect of local urokinase delivery on platelet deposition after balloon angioplasty. Platelet deposition was measured as described by Johnstone et a130 using`In-labeled platelets.`In-tropolone was prepared by mixing 50 gg tropolone (Sigma Chemical Co) in normal saline solution with 0.5 mCi of`'In-chloride (New England Nuclear). Forty-three milliliters of whole blood was withdrawn into 7 mL ACD saline (Mallinckrodt) and centrifuged at 180g for 15 minutes. Platelet-rich plasma was removed and centrifuged at 1600g for 10 minutes. The platelet pellet was then resuspended with`'In-tropolone and 2 mL ACD saline solution for 20 minutes and centrifuged for 10 minutes at 1600g. The pellet was resuspended in 4 mL platelet-poor plasma, incubated for 5 minutes, and centrifuged for 10 minutes at 1600g. The labeled platelet pellet was resuspended in 5.5 mL platelet-poor plasma and centrifuged at lOOg for 10 minutes to remove any macroaggregates. The supematant containing`'In-labeled platelets was then removed and reinjected intravenously.
Approximately 2 hours after reinjection of labeled platelets, all animals were premedicated with tiletamine/zolazepam (100 mg IM) and atropine (2 mg IM) and then endotracheally intubated. Anesthesia was maintained with enflurane and ventilation provided by a volume respirator. Using standard surgical techniques, short 1-cm, 9F introducer sheaths (USCI) were inserted into both carotid and both femoral arteries approximately 10 cm distal to the aorta by direct arterial exposure.
Before angioplasty, intravascular ultrasound using a 20-MHz, 3.5F catheter (Mansfield/Boston Scientific) was performed on both carotid and iliac arteries to assess arterial diameter and also to localize the site of balloon inflation measured from the origin of the vessel from the aorta. Imaging was performed with a console adapted for 20-MHz operation and 3600 scans (Diasonics).
In all pigs, balloon angioplasty was subsequently performed on an iliac and carotid vessel using a urokinase-coated hydrogel balloon. All balloons were loaded with urokinase by immersion into a concentrated solution of Abbokinase (50000 U/mL) for 60 seconds. Balloon dilatation using a same-sized hydrogel balloon that had been immersed into saline was performed in the contralateral iliac or carotid vessel to serve as a control. All inflations were performed for 5 minutes at 6 atm with a balloon-to-artery ratio of approximately 1.3:1, as assessed by intravascular ultrasound. Balloon sizes for the entire study group ranged from 7 to 8 mm.
One hour after angioplasty, all dilated arterial segments were excised, flushed gently with saline, stripped of adventitia, and counted in a gamma well counter. A symmetric 50-keV window centered around the 247-keV peak was used to measure "'In. Blood samples for determination of free and cell-bound "'In activity were also obtained at the time of angioplasty and vessel removal. The number of platelets deposited in the treated vessel was determined by multiplying the number of "'.In counts per minute in the vessel by the number of platelets per milliliter of blood and dividing by the "'In counts per minute per milliliter of blood.
All animal studies, including both rabbit and porcine protocols, conformed to the principles of the American Physiological Society.
Clinical Studies
Fifteen consecutive patients with intracoronary thrombus seen on coronary angiography were treated with urokinasecoated balloons. All balloons were coated with urokinase by immersion into a concentrated Abbokinase solution (50 000 U/mL) for at least 60 seconds. Intracoronary thrombus was identified as a clearly localized, discrete intraluminal filling defect that was surrounded by contrast medium and was seen in multiple angiographic views. In 10 patients, urokinasecoated balloons were used after failure of conventional balloon angioplasty due to abrupt thrombotic closure or persistent intracoronary thrombus with slow antegrade flow. In an additional 5 patients, urokinase-coated balloons were used as primary therapy for treatment of thrombus-containing lesions.
Statistics
Mean and standard deviation for the amount of fluid and number of urokinase units absorbed by hydrogel and nonhydrogel balloons and for urokinase units delivered to the arterial wall were determined for in vitro and in vivo pharmacokinetic studies. Differences in urokinase loading with different loading techniques and washoff of urokinase from balloon surfaces were assessed using one-way ANOVA. Intergroup comparisons of urokinase loading and washoff between hydrogel and nonhydrogel balloons were determined using paired t tests.
Mean and standard deviation for "'In-labeled platelets were determined for in vivo platelet studies. Differences in platelet deposition between urokinase-treated and control vessels were analyzed using the Wilcoxon signed rank test.
For clinical studies, all angiograms were reviewed in a blinded fashion by two observers who independently evaluated the angiographic presence of intracoronary thrombus and the grade of TIMI coronary flow. Differences were resolved by consensus.
A probability value less than .05 was considered significant. All patients who demonstrated abrupt closure or slow antegrade flow subsequently underwent balloon dilatation with a urokinase-coated balloon that had been immersed in a solution of 50 000 U/mL Abbokinase. In each patient, the urokinase-coated balloon was the same size as the conventional angioplasty balloon. A total of 2.3±0.7 inflations (range, one to three) with a mean inflation time of 182±75 seconds per inflation (range, 60 to 300 seconds) at 9.1±2.2 atm (range, 5 to 12 atm) were performed. After the initial urokinase balloon dilatation, all patients demonstrated vessel patency with TIMI grade 3 in 9 patients and TIMI grade 2 in 1. In addition, as seen angiographically, there was complete dissolution of intraluminal clot in all patients. Angiographic evidence of distal embolization did not occur in any patient.
Results
In an additional 5 patients, urokinase-coated balloons were used as the primary treatment of thrombus-containing stenoses. In 1 of these patients, abrupt closure with TIMI grade 0 flow developed despite pretreatment with 500 000 U intracoronary Abbokinase over 1 hour. After dilation with a urokinase-coated balloon, successful lesion reduction with complete dissolution of intracoronary thrombus, TIMI grade 3 coronary flow, and no evidence of distal embolization occurred in all patients.
After local urokinase delivery, all patients were treated with intravenous heparin, aspirin and a combination of nitrates, calcium channel blockers, and fl-blockers. No patient demonstrated clinical evidence of coronary reocclusion or increased elevation of baseline cardiac enzymes after angioplasty. One of the patients who initially presented with postinfarction cardiogenic shock died 11 days after angioplasty from progressive pump failure. The remaining patients were all discharged from the hospital. Table 5 lists demographic and angiographic data for patients treated with urokinase-coated balloons for abrupt thrombotic closure, and Table 6 describes patients in whom urokinase-coated balloons were used as the primary therapy. 
Discussion
This study demonstrates that urokinase-coated hydrogel balloons are effective in the local inhibition of platelet deposition and the treatment of intracoronary thrombus and thrombus-containing stenoses during balloon angioplasty. In vitro and in vivo pharmacokinetic studies have shown that hydrogel balloons absorb and retain more urokinase than standard, nonhydrogel balloons and are capable of transferring urokinase from the hydrogel surface to the arterial wall during balloon inflation. In vivo animal studies have demonstrated that this technique significantly reduces early platelet deposition after balloon injury. Most importantly, clinical studies have shown that this technique was successful in Definitions are as in Table 5 , and CFX, circumflex. *Total occlusions.
treating intracoronary thrombus and reversing abrupt thrombotic closure in patients unsuccessfully treated with conventional balloon angioplasty.
Potential Mechanisms of Action The presumed mechanism of platelet deposition inhibition and enhanced intracoronary thrombolysis with urokinase-coated balloons is the delivery of a relatively small amount of urokinase from the hydrogel coating on the balloon surface directly to the angioplasty site. Hydrogel compression during balloon inflation facilitates diffusion of urokinase off the polymer into the space between the balloon surface and arterial wall and also directly into the arterial wall. Urokinase retained on the balloon surface, intramurally deposited in the arterial wall, and eluted from the hydrogel may act directly on circulating plasnminogen within the vicinity of balloon inflation or on plasminogen trapped within thrombus to create plasmin.
Local urokinase delivery may limit platelet deposition by resulting in plasmin lysis of fibrinogen and fibrin forming at the angioplasty site and subsequently dissolving platelet aggregates. Delivered immediately at the time of angioplasty, the early thrombolytic effects exerted by the enzyme on platelet thrombi may interfere with the positive feedback mechanisms leading to additional platelet deposition, resulting cumulatively in less platelet deposition hours later after initial balloon injury.
In the presence of preexisting intracoronary thrombus, local delivery of urokinase with the hydrogel system may result in a relatively high urokinase concentration in thrombus "trapped" between the balloon surface and arterial wall. Previous in vitro studies with human plasma have demonstrated that a urokinase concentra- Intracoronary thrombus is an extremely common problem observed in the cardiac catheterization laboratory. The incidence of intracoronary thrombus ranges from 6% to 15% in patients referred for percutaneous revascularization and from 40% to 90% in patients with unstable coronary syndromes.33-37 Conventional balloon angioplasty in the presence of intracoronary thrombus may result in abrupt closure rates as high as 73%, in distal embolization rates as high as 31%, and in an incidence of no-reflow phenomenon as high as 7%.38 These suboptimal results are related to the fact that angioplasty itself is a powerful thrombogenic stimulus because it exposes additional wall components to circulating platelets and may result in the release of platelet factor IV and fibrin-bound thrombin from intraluminal clots. A no-reflow phenomenon may also occur secondary to the release of potent microvascular vasoconstrictors such as thromboxane and serotonin. 39 Current pharmacological therapies for treating intracoronary thrombus have focused on the administration of antiplatelet, antithrombin, and thrombolytic agents either systemically or locally.'5-25 Multiple nonrandomized studies have demonstrated the efficacy of administering urokinase and other thrombolytic agents using a variety of regimens when thrombus is present or when it develops during percutaneous transluminal coronary angioplasty.18-25 More recently, enhanced thrombolysis has been demonstrated with the use of prolonged urokinase infusions (eg, 18 to 48 hours) through a subselective catheter. 24, 25 Local delivery of urokinase to the site of intracoronary thrombus with hydrogel balloons may have specific advantages over current pharmacological regimens. One obvious advantage of the hydrogel technique is that it may avoid the need for prolonged administration of antithrombin and thrombolytic agents that lengthen the patient's hospitalization and catheterization procedure. A second advantage of this approach is that a much lower dose of urokinase can be administered to the patient but in high local concentrations directly to the thrombus, thereby preventing systemic thrombolysis and subsequent bleeding complications. This may be particularly useful in patients who have contraindications to systemic thrombolysis. A final advantage of the hydrogel system is that it uses mechanical modification of the thrombus during balloon inflation, which may further enhance thrombolysis by exposing more thrombus surface to urokinase. In addition, angioplasty itself reduces the stenosis that limits flow and promotes stasis.
Study Limitations
Although locally delivered urokinase improved angiographic findings in patients in this study, it is impossible to rule out the possibility that these results occurred simply secondary to the effects of conventional angioplasty. Multiple prolonged inflations may eventually result in the angiographic disappearance of thrombus. The angiographic identification of intracoronary thrombus likewise has its limitations.35,36 A randomized, controlled trial of local urokinase delivery, perhaps involving coronary angioscopy to identify thrombus, would be necessary to fully ascertain the benefit of this technique.
Conclusions
Local urokinase delivery with a hydrogel system is possible and appears to be efficacious in reducing early platelet deposition after experimental balloon angioplasty and in treating intracoronary thrombus and thrombotic abrupt closure in patients. The presumed mechanism of this technique involves trapping of thrombus in a local environment of high urokinase concentration, with enhanced thrombolysis. In addition, there may be a persistent thrombolytic effect at the angioplasty site from intramurally deposited drug. A randomized, controlled trial of this therapy may be useful in fully evaluating the efficacy of this technique.
